Peer Review History

Original SubmissionAugust 29, 2024
Decision Letter - Ashraf Elbahrawy, Editor

PONE-D-24-37385A Novel Real-Time Ultrasound-Based Imaging Analysis Software for Monitoring Radiofrequency Ablation and Visualizing Ablation AreasPLOS ONE

Dear Dr. Sato,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 25 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ashraf Elbahrawy

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.

3. Thank you for stating the following financial disclosure:

“This work was supported by the Health, Labor, and Welfare Policy Research Grants from the Ministry of Health, Labor, and Welfare of Japan (Policy Research for Hepatitis Measures [H30-Kansei-Shitei-003]).”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This work was supported by the Health, Labor, and Welfare Policy Research Grants from the Ministry of Health, Labor, and Welfare of Japan (Policy Research for Hepatitis Measures [H30-Kansei-Shitei-003]).”

We note that you have provided funding information that is currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This work was supported by the Health, Labor, and Welfare Policy Research Grants from the Ministry of Health, Labor, and Welfare of Japan (Policy Research for Hepatitis Measures [H30-Kansei-Shitei-003]).”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

Please update your Data Availability statement in the submission form accordingly.

6. In the online submission form you indicate that your data is not available for proprietary reasons and have provided a contact point for accessing this data. Please note that your current contact point is a co-author on this manuscript. According to our Data Policy, the contact point must not be an author on the manuscript and must be an institutional contact, ideally not an individual. Please revise your data statement to a non-author institutional point of contact, such as a data access or ethics committee, and send this to us via return email. Please also include contact information for the third party organization, and please include the full citation of where the data can be found.

7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

8. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I would like to thank you for this interesting , novel and creative work.

I just want few explained points.

1. as regard mentioned HCCs, were they the first time to be treated and assessed (i mean, not treated before).

2. In your opinion, what is the expected time to apply bio trace map , (during ablation, or short time after ablation)

3. What would happen, if we re ablated the same lesion at the same time time due to insufficient ablation.?. Would bio trace map work well?

4.Is there a difference in results, if we compare the efficacy of bio trace map in different segments of liver?

.

At the end , I am appreciating this impressive work.

Thanks for all authors.

Reviewer #2: The authors of this manuscript presented a novel Real-Time Ultrasound-based imaging analysis software for monitoring radiofrequency ablation and visualizing ablation areas. This title is worthy of investigation and the study is well organized and well structured. However, some comments are mentioned below that need more clarification, explanation, or modification.

1. The abstract of the study is better to be structured.

2. All the abbreviations in the manuscript like CT, MRI, etc. should first be mentioned in their complete forms followed by their abbreviated forms.

3. Please mention the type of study in the method section.

4. How many times each experiment was applied? Please explain.

5. Was the sample size enough to reach an accurate and robust result? Please explain.

6. Did your study involve any sort of follow-ups or not?

7. Please mention exactly the control groups that you have utilized in your study.

Wish you luck and prosperity in revising the manuscript.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mohammed ElFayoumie

Reviewer #2: Yes: Ali Kashkooe

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: Reviewer comments and recommendations.docx
Revision 1

Point-by-point responses to the reviewers’ comments:

Reviewer 1

Generally

1. As regard mentioned HCCs, were they the first time to be treated and assessed (I mean, not treated before).

[Response]

While some patients may have had previous treatments with radiofrequency ablation (RFA) for other lesions, the specific lesions included in this study were being treated for the first time. We have added the following to our manuscript.

Page 7, “Patients and procedures”

HCC lesions included in this study were undergoing initial treatment.

2. In your opinion, what is the expected time to apply bio trace map (during ablation, or short time after ablation).

[Response]

We appreciate the reviewer’s comment for pointing out an important point. BioTrace map is expected to be used in real time during ablation to confirm the adequacy of the margins in a clinical practice. We revised our manuscript as follows.

Page 14, first paragraph

In clinical practice, the BioTrace map is expected to be used in real time during ablation to confirm the adequacy of the margins. This approach ensures that sufficient tissue has been ablated and helps identify any areas needing further treatment. Additionally, the BioTrace system offers advantages over CT for intra-operative monitoring, as it provides comparable performance in assessing the treatment response of radiofrequency ablation (RFA). This capability could lead to a reduction in patient radiation exposure in the future, enhancing the safety and effectiveness of the procedure.

3. What would happen, if we re ablated the same lesion at the same time due to insufficient ablation?

[Response]

BioTrace utilizes a proprietary algorithm to analyze the temporo-spatial behavior of thermal gas bubble activity during ablation. If re-ablation is performed, BioTrace similarly analyzes the new gas bubble activity and generates an updated heat map reflecting the additional tissue damage in real time. This would allow us to visualize the extended ablation area and assess the effectiveness of the repeated ablation.

We have added this information to our manuscript as follows.

Page 15, second paragraph

In cases of re-ablation due to insufficient ablation, BioTrace may be used to analyze the new gas bubble activity and to generate an ablation map in real time, allowing us to visualize the extended ablation area and assess the effectiveness of the repeated ablation. However, further investigation is needed to verify these observations and fully understand their implications in clinical practice.

4. Is there a difference in results, if we compare the efficacy of bio trace map in different segments of liver?

[Response]

We conducted an ANOVA test to examine the differences among the liver segments. Although our sample size was limited, the analysis did not reveal any statistically significant differences in efficacy across the different segments.

We have added the following to our manuscript.

Page 11, second paragraph

To address the differences in efficacy of the BioTrace map across different liver segments, we employed an analysis of variance (ANOVA) test.

Page 12, second paragraph of “Predictive accuracy of BioTrace Map for demonstrating the ablated area”

The ANOVA test did not reveal differences based on the tumor’s localized segment (p = 0.4).

Table 2

We added a column for “Tumor segment”.

Reviewer 2

1. The abstract of the study is better to be structured.

[Response]

According to the reviewer’s comment, we have structured the abstract.

2. All the abbreviations in the manuscript like CT, MRI, etc. should first be mentioned in their complete forms followed by their abbreviated forms.

[Response]

We appreciate the reviewer’s comment. In accordance with the reviewer’s comment, we have spelled out all abbreviations upon their first appearance in the manuscript.

3. Please mention the type of study in the method section.

[Response]

According to the reviewer’s comment, we have included a note specifying that the study is a prospective observational study as follows.

Page 7, “Method” section

This study is a prospective observational study, aiming to evaluate the real-time monitoring capabilities of BioTrace system.

4. How many times each experiment was applied? Please explain.

[Response]

Each experiment involving the BioTrace system was conducted once. This was due to the exploratory nature of this study. We have added this information to our manuscript as follows.

Page 11, second paragraph

Due to the exploratory nature of this study, each experiment involving the BioTrace system was conducted once.

5. Was the sample size enough to reach an accurate and robust result? Please explain.

[Response]

The sample size of 20 cases may not be sufficient to draw definitive conclusions about the robustness and accuracy of the results. This study is intended as a preliminary investigation to explore the potential of the BioTrace system, and we acknowledge that further studies with larger sample sizes are required to validate our findings and ensure their generalizability. We have added this clarification to the discussion section as follows.

Page 15, second paragraph

The limitation of this study is its small sample size of 20 cases, which may not be sufficient to draw definitive and robust conclusions regarding the efficacy and accuracy of the BioTrace system.

6. Did your study involve any sort of follow-ups or not?

[Response]

Although we are currently considering a follow-up study to further evaluate the long-term effects of the BioTrace system, the current study does not include follow-up procedures to draw conclusions regarding the efficacy and accuracy of the BioTrace system. We have included this limitation in our manuscript as follows. We have added this limitation to our manuscript as follows.

Page 15, second paragraph

Additionally, the study did not involve any follow-up procedures, which limits our ability to assess the long-term impact and outcomes of the BioTrace system.

7. Please mention exactly the control groups that you have utilized in your study.

[Response]

The current study do not include a control group. The objective of this study is to evaluate the predictive capabilities of the BioTrace system by comparing its performance against radiologist-annotated ablation zones using contrast-enhanced CT as the reference standard.

We have added this limitation to our manuscript as follows.

Page 16, first paragraph

Finally, the study did not include a traditional control group, which limits the ability to demonstrate the added clinical value of the BioTrace system. Further studies are needed to assess the potential clinical benefits and added value of the BioTrace system in a controlled setting.

Decision Letter - Ashraf Elbahrawy, Editor

PONE-D-24-37385R1A Novel Real-Time Ultrasound-Based Imaging Analysis Software for Monitoring Radiofrequency Ablation and Visualizing Ablation AreasPLOS ONE

Dear Dr. Sato,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 01 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ashraf Elbahrawy

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #3: In the current study you compared performance of BTM( pre ablation prediction) with CECT 24 hours after ablation, please mention this in a clear statement in methodology section. In addition, BTM system is not activated during the procedure in the current study. So I think the title should be modified express the work in the study.

Please revise the following:

((A Novel Real-Time Ultrasound-Based Imaging Analysis Software for Monitoring Radiofrequency Ablation and Visualizing Ablation Areas))

In the current study you said in page 15” Although the current system has been designed for real-time monitoring, it was not activated during the procedure in this study.

Page 14” It provides comparable performance in assessing the treatment response of radiofrequency ablation (RFA).”

Unfortunately, the study design is not compatible with prospective observational study! You compared performance of BTM with CECT 24 hours after ablation in the same group.

What is/are the extra benefit/s expected from BTM in contrast to ablation under the guidance of contrast-enhanced ultrasonography? Both are ultrasound based and real time technique!

Page 8, you mentioned “The dynamics of microbubbles, reflecting the tissue’s response to heat, varies according to the applied temperature” I think there are multiple variables other than temperature should be considered e.g., biological nature of lesion, pathological background of liver. I mean HCC on top of chronic hepatitis, cirrhosis or viral VS metabolic liver disease, fibrotic load within the liver,……

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mohammed Elfayoumie

Reviewer #3: Yes: Ali Madian

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

Point-by-point responses to the reviewers’ comments:

Reviewer 3

1. In the current study, you compared performance of BTM (pre ablation prediction) with CECT 24 hours after ablation, please mention this in a clear statement in methodology section. In addition, BTM system is not activated during the procedure in the current study. So I think the title should be modified express the work in this study.

Please revise the following:

((A Novel Real-Time Ultrasound-Based Imaging Analysis Software for Monitoring Radiofrequency Ablation and Visualizing Ablation Areas))

In the current study you said in page 15” Although the current system has been designed for real-time monitoring, it was not activated during the procedure in this study.

Page 14” It provides comparable performance in assessing the treatment response of radiofrequency ablation (RFA).”

Unfortunately, the study design is not compatible with prospective observational study! You compared performance of BTM with CECT 24 hours after ablation in the same group.

[Response]

We agree that the methodology and title should be clarified to better reflect the nature of our study.

We modified the title of our manuscript as follows

Page 1, Title

Retrospective Evaluation of a Novel Ultrasound-Based Imaging Analysis Software for Predicting Radiofrequency Ablation Areas

We have added the following statement in the Method section under "Performance evaluation of BioTrace and statistical analysis” as follows.

Page 7, “Patients and procedures”

This study is a retrospective analysis of prospectively collected ultrasound imaging data, aiming to evaluate the predictive capabilities of the BioTrace system.

Page 9, “Performance evaluation of BioTrace and statistical analysis”

In this study, we retrospectively analyzed the ablation areas by comparing the BioTrace prediction generated from ultrasound imaging data collected during the RFA procedure with the actual ablation zones confirmed by CECT obtained 24 hours post-treatment, which is considered the gold standard. While the BTM system is designed for real-time monitoring, it was not activated during the procedures in this study. Instead, we retrospectively applied the BioTrace algorithm to the prospectively collected ultrasound imaging videos to generate the ablation prediction maps.

Regarding the description on page 14 and page 15 (in the pre revise version), we have addressed the issues and revised the manuscript as follows.

Page 15, first paragraph

Additionally, the BioTrace system demonstrated comparable performance to CT in assessing ablation zones in this retrospective analysis, suggesting potential advantages for future intra-operative monitoring applications.

Page 16, second paragraph

While the BioTrace system is designed for real-time monitoring, this validation study focused on retrospective analysis of prospectively collected ultrasound imaging data. The real-time monitoring capabilities will be evaluated in future prospective clinical trials.

2. What is/are the extra benefit/s expected from BTM in contrast to ablation under the guidance of contrast-enhanced ultrasonography? Both are ultrasound based and real time technique!

[Response]

We appreciated the reviewer’s important question regarding the advantages of BioTrace (BTM) compared to contrast-enhanced ultrasonography. The BioTrace system offers several distinct advantages over contrast-enhanced ultrasonography (CEUS). First, it minimizes the resources required for contrast agent preparation and administration. Second, unlike CEUS which requires low acoustic pressure to maintain microbubble stability, BioTrace can utilize optimal ultrasound settings to maintain high-quality B-mode imaging throughout the procedure. This allows for better visualization of the target area and surrounding structures during ablation.

We have added the current information to our manuscript as follows.

Page 14, third paragraph

The BioTrace system offers several distinct advantages over contrast-enhanced ultrasonography. First, it minimizes the resources required for contrast agent preparation and administration. Second, unlike CEUS which requires low acoustic pressure to maintain microbubble stability, BioTrace can utilize optimal ultrasound settings to maintain high-quality B-mode imaging throughout the procedure. This allows for better visualization of the target area and surrounding structures during ablation.

3. Page 8, you mentioned “The dynamics of microbubbles, reflecting the tissue’s response to heat, varies according to the applied temperature” I think there are multiple variables other than temperature should be considered e.g., biological nature of lesion, pathological background of liver. I mean HCC on top of chronic hepatitis, cirrhosis or viral VS metabolic liver disease, fibrotic load within the liver,……

[Response]

We understand the reviewer’s comment. We have revised the manuscript to better reflect the complexity of these factors influencing the ablation process as follows.

Page 8, second paragraph

The dynamics of microbubbles reflect a complex interaction of multiple variables during thermal ablation. While temperature is a primary factor, the microbubble behavior is also influenced by: (1) the biological nature of the lesion, (2) the underlying pathological condition of the liver (such as chronic hepatitis, cirrhosis, or metabolic liver disease), (3) the degree of liver fibrosis, (4) local tissue perfusion characteristics, and (5) the applied temperature. These variables collectively affect the formation and the dynamic behavior of microbubbles during thermal ablation.

We also added the text to emphasize the need for further investigation across different liver conditions to better understand these complex interactions as follows.

Page 16, second paragraph

Furthermore, the influence of various liver pathologies and tissue characteristics on microbubble dynamics requires additional investigation. Future studies should evaluate the system's performance across different pathological conditions, including chronic hepatitis, cirrhosis, and varying degrees of liver fibrosis, to better understand how these factors affect the accuracy of ablation zone prediction.

Attachments
Attachment
Submitted filename: Response to Reviewers letter20241227.docx
Decision Letter - Ashraf Elbahrawy, Editor

Retrospective Evaluation of a Novel Ultrasound-Based Imaging Analysis Software for Predicting Radiofrequency Ablation Areas

PONE-D-24-37385R2

Dear Dr. Sato,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ashraf Elbahrawy

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Formally Accepted
Acceptance Letter - Ashraf Elbahrawy, Editor

PONE-D-24-37385R2

PLOS ONE

Dear Dr. Tateishi,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Ashraf Elbahrawy

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .